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Correspondence: Tim Lammens (e-mail: tim.lammens@ugent.be).Pediatric acute myeloid leukemia (pedAML) is a rarehematological disease accounting for 20% of allpediatric leukemias.1 Current chemotherapeutic regi-mens have reached a survival plateau around 70%.2,3
Still 30% to 40% of the good responders experience relapse, and
especially patients with fms-like tyrosine kinase receptor-3
internal tandem duplications (FLT3-ITD) show a detrimental
outcome.2 These observations have driven the development of
alternate therapeutic strategies, including targeting antibodies
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1transgenic cytotoxic T-cells (CTLs). However, besides FLT3
inhibitor-based therapies4,5 and CD33-directed agents,6
targeted strategies have not yet found their way into treatment
protocols.
We recently identified the TCR g chain alternate reading frame
protein (TARP) as an immunotherapeutic target in leukemic
blasts (L-blast) and in leukemic stem cells (LSC) of adults and
children with AML.7 TARP was previously only reported in
androgen-sensitive prostate and breast adenocarcinoma.8
Although TARP was upon its discovery described as a
truncated TCRg transcript encoding the first TCR g chain
constant domain (TRGC1), we found that an AML-exclusive,
TRGC2-encoding TARP transcript co-exists in AML.7 The
high sequence homology between TRGC1 and TRGC2
hampers distinction through conventional techniques. Here,
we used mRNA sequencing to demonstrate both TARP
transcripts in four wild type (WT) AML cell lines with
documented TARP expression.7 We confirmed that TRGC1
and TRGC2 transcript are highly expressed inMV4;11, next to
a moderate expression in HL-60 and THP-1, while negative in
OCI-AML3 (Fig. S1A, http://links.lww.com/HS/A77). To gain
insight into the biological relevance of both transcripts,
transgenic TARP knockdown (TARP-KD) cell lines were
generated for 2/4 AML cell lines, HL-60 and MV4;11, by
retroviral transduction of TARP-targeting short-hairpin
(shRNA) encoding viral particles, next to a mock construct.7
In MV4;11, both TRGC1 and TRGC2 transcripts were
suppressed upon TARP knockdown. In HL-60, only the
TRGC2 transcript was significantly downregulated compared
to mock and WT, while TRGC1 showed a two-fold decrease
(Fig. S1B, Table S1, http://links.lww.com/HS/A77). Altogether,
these data confirm that both TRGC1- and TRGC2-encoded
TARP transcripts co-exist in AML cell lines, and are targetable.
Our previous data suggested that TARP peptides are
adequately MHC-presented, as leukemic cells could be targeted
in vitro by cytotoxic T-cells (CTLs) retrovirally transduced with a
TCR directed against the HLA-A2 enhanced affinity TARP
(P5L)4-13 epitope.
7 However, whether recognition of tumor
TARP peptide-MHC complexes (p-MHCs) by TCR-bearing
CTLs is able to trigger antigen-specific immune responses in vivo
still needs to be elucidated. To this end, TARP-TCR expression
on CTLs isolated from pedAML patients was measured using
HLA-A∗0201-restricted, PE-conjugated tetramers directed
against the TARP(P5L)4-13 epitope, kindly provided by
the NIH Tetramer Core Facility. Lymphocytes from TARP-high
Figure 1. Tetramer staining of TARP-TCR+ CTLs from pedAML patients. The lymphocyte gating strategy, described in Supplemental Materials, is illustrated
in (A). The total lymphocyte compartment is indicated in green, other white blood cells in blue en non-viable cells or doublets in dark grey. Subsequent patient-
individual gating of the CD3+/CD8+ compartment, and tetramer staining within this compartment, is shown for three TARP-high/HLA-A∗0201 positive patients in
(B-D). Tetramer-positive events, defining TARP-TCR+ CTLs, are indicated in black, and tetramer-negative CTLs in light grey. Non-CD3+/CD8+ cells within the
lymphocyte gate are indicated in green. Median MFI values are indicated by circles. Tetramer positivity was gated for each patient individually based on sample-
specific FMO controls. For two out of the three patients (B-C), both BM and PB were analysed. For one of the three patients (B), lymphocytes from both diagnosis
and relapse could be evaluated. BM=bone marrow, CTL=cytotoxic T-cell, FMO=fluorescence-minus-one, PB=peripheral blood, TARP=T-cell receptor g chain
alternate reading frame protein, TCR=T-cell receptor.
B. Depreter et al. TARP in Pediatric AML(n=5, 3/5 HLA-A∗0201 positive) and TARP-low (n=6, 5/6
HLA-A∗0201 positive) pedAML patients were surface- and
tetramer-stained and measured on a FACSCanto II flow
cytometer (BD Biosciences).
All three TARP-high/HLA-A∗0201-positive pedAML patients
showed a positive tetramer staining within the CD3+/CD8+
compartment (median 2.4%, median MFI 357) (Fig. 1). MFI
values were comparable between BM and PB as evaluated for 2/3
patients. TARP-TCR expression was higher at relapse compared
to diagnosis in both PB and BM, as measured in one patient.
Higher intensity tetramer staining can be associated with a higher
TCR and/or co-receptor expression, and/or to a higher TCR
avidity. This observation may relate to an achieved immunity for
the tumor epitope, that is, the presence of resting CD8+ memory
T-cells that rapidly reactivate and upregulate TCR expression
upon p-MHC re-stimulation,8 or the presence of a T-stem cell
pool generated during the initial immune response.9 If this
hypothesis holds true, CTL priming by TARP vaccination after/
during chemotherapy could be a therapeutic strategy. More
diagnosis-relapse couples are needed to confirm this finding.
Tetramer-positive CTLs from pedAML patients showed a
fivefold lower TARP-TCR expression than the positive control
(median MFI=1793). No tetramer-positive population could be
measured in the CTL compartment from TARP-high/HLA-
A∗0201 negative patients (n=2), TARP-low/HLA-A∗0201
positive patients (n=5) or TARP-low/HLA-A∗0201 negative
(n=1) patients.
Altogether, these data suggest that a pedAML patient’s native
immune response is triggered by HLA-presentation of TARP
antigenic peptides in vivo, but, apparently insufficiently to2eradicate the leukemic cells. Both leukemic cell resistance and
lymphocyte quiescence may account for this finding.10 Also, due
to T-cell ignorance, tumor-specific CTLs may be present but not
primed by the antigen, or priming may be inefficient.11 Gaining a
deeper understanding of the underlying mechanisms may
contribute to therapeutic targeting of TARP in pedAML.
We previously showed that TARP expression is associated
with FLT3-ITD in pedAML. Unfortunately, the initial pediatric
sample cohort was too small to evaluate a possible clinical impact
of TARP expression. We here evaluated TARP expression in a
larger cohort of LSC (n=24) and L-blast (n=29) cells sorted
from pedAML patients using real-time quantitative PCR (qPCR),
and compared expression levels to those measured in HSC (n=
25) and C-blast (n=28) sorted from healthy controls.
Data analysis is described in Supplemental, and expression
values were expressed as calibrated normalised relative quantities
(CNRQ).
A significantly increased TARP expression (p< .0001) was
demonstrated in LSC and L-blast compared to their healthy
counterparts (Fig. S2A, http://links.lww.com/HS/A77). PedAML
patients were dichotomized as TARP-high (n=13/29, 44.8%)
and TARP-low (n=16/29, 55.2%), using a cut-off based on the
average expression measured in healthy controls plus 2 times the
standard deviation (Table S2, http://links.lww.com/HS/A77).
The presence of translocations, including core-binding factor
leukemia, was significantly inversely correlated to TARP
expression (p< .01 and< .0001, respectively). FLT3-ITD muta-
tions (p< .0001) and HR profiles (p< .01) were exclusively
observed inTARP-high patients (Fig. 2A).Within theTARP-high
group, a significantly higher proportion of patients showedWBC
Figure 2. TARP transcript expression in pedAML in relation to subgroups and outcome. Correlation between patient characteristics and outcome between
pedAML patients dichotomized as TARP-low (n=16) and TARP-high (n=13). TARP expression was measured by qPCR, and CNRQ values were interpreted
against a cut-off calculated based on the expression in healthy controls (see Supplemental Materials, http://links.lww.com/HS/A77). p values<.05 were considered
as significant. One, two, three or four asterisks are indicative for the level of significance (p< .05, p< .01, p< .001 and p< .0001, respectively). (A) Bars display the
percentage of patients (%), harboring the characteristic shown in the x-axis, for TARP-high (black) and TARP-low (white) pedAML. The total number of patients
positive for each characteristic is shown between parentheses. (B) Differential TARP expression between FLT3-ITD mutated and FLT3 WT pedAML patients
measured in the LSC and L-blast compartment. FLT3-ITD mutated pedAML showed a significantly higher TARP expression in both LSC (p< .0001) and L-blast
(p< .0001). Thirteen out of the 29 pedAML patients were classified as TARP-high, that is, 11/11 FLT3-ITD pedAML and 2/18 FLT3WT pedAML (encoded by “18”
and “25”). Horizontal bars indicate means, error bars indicate ±SEM, horizontal square brackets represent statistical comparisons and the dotted line represent the
cut-off for elevated TARP expression. (C-D) Kaplan–Meier EFS and OS survival plots based on 15 pedAML treated in the NOPHO-DBH AML2012 protocol,
dichotomized as TARP-high (n=6, 4/6 FLT3 ITD and 2/6 FLT3 WT) or TARP-low (n=9, 9/9 FLT3 WT). The number of days is shown on the x-axis, and the
percentage as a ratio (100% equals 1.0) on the y-axis. Drop-outs of the patients are indicated at the bottom per block of 250 days. (C) EFS was significantly lower in
TARP-high versus TARP-low patients (16.7% vs 77.8%, respectively, p< .01). (D) OS was lower in TARP-high vs TARP-low patients (66.7% versus 88.9%,
respectively), though at a non-significant level (p> .05). AK=abnormal karyotype, BM=bone marrow, CEBPA=CCAAT/enhancer-binding protein alpha, CNRQ=
calibrated normalized relative quantity, CNS=central nerve system, F= female, FAB=French-British-American, FLT3= fms-like tyrosine kinase receptor-3, HR=
high risk, ITD= internal tandem duplication, LSC= leukemic stem cell, L-blast= leukemic blast, M=male, MT=mutated, NK=normal karyotype, NPM1=
nucleophosmin, PB=peripheral blood, PedAML=pediatric acute myeloid leukemia, qPCR=quantitative polymerase chain reaction, SEM=standard error of the
mean, SR=standard risk, TARP=T-cell receptor g chain alternate reading frame protein,WT1=Wilms’ tumor 1, WBC=white blood cell, WT=wild type, yr=years.
(2020) 4:2 www.hemaspherejournal.comcounts >30  109/L and blasts >70% in BM and >50% in PB
(p< .05).
In concordance with our previous work, TARP transcript
expression was significantly increased in LSC and L-blast
(p< .0001) from FLT3-ITD pedAML (n=11) compared to
FLT3 WT pedAML (n=18) (Fig. 2B). Sixty-three percent of
FLT3-ITD positive patients harbored a single ITD, 27% two
ITDs and one patient presented four ITDs (Table S3, http://
links.lww.com/HS/A77). The length of the duplicated region
ranged between 20 and 96 base pairs (bp) (median 33bp), and
allelic ratios (ARs) varied from 2.7 to 70.8% (median 17.7%).
There was no significant association between the number of3ITDs and the level of TARP expression. One patient presented
only a single FLT3-ITD clone with an AR of 3.0%, but was still
classified as TARP-high. Paired comparison of TARP expres-
sionmeasured in LSCs and L-blasts sorted from 9/11 FLT3-ITD
mutated pedAML demonstrated a significantly higher expres-
sion in the latter compartment (p= .041, Fig. S2B, http://links.
lww.com/HS/A77). This finding is in agreement with our
published micro-array data of paired LSC and L-blast couples
(GSE 128103).
Two FLT3 WT pedAML patients showed elevated TARP
expression in LSCs and L-blasts (pedAML18 and pedAML25).
The presence of TRGC rearrangements, able to confound TARP
B. Depreter et al. TARP in Pediatric AMLexpression due to commonTRGCcoding regions and sporadically
observed in AML,12 was excluded. FLT3-ITD analysis was
repeated on L-blast subpopulations to exclude a possible false
negative result (not performed in LSC due to too low DNA
concentration). One patient (pedAML18) harbored a rare
KMT2A-SEPT9 fusion protein, presented central nerve system
(CNS) invasionandwas classifiedasHR.Theotherpatient showed
a normal karyotype and WT1 overexpression. Both TARP-high/
FLT3 WT patients with and without KMT2A-SEPT9 relapsed
after 8.4 months and presentedwith resistant disease, respectively.
The first patient died 15.1 months after diagnosis.
Among NOPHO-DBH AML2012-treated patients (n=15),
TARP-high pedAML (n=6) showed a significantly lower event-
free survival (EFS) compared toTARP-lowpedAML (n=9) (16.7%
vs 77.8%, respectively, logrank p< .01, Fig. 2C). Relapse occurred
in 3/6TARP-high patients and 2/6 showed resistant disease, with an
estimated time to event of 6.6 months. Two of the nine TARP-low
patients also relapsed, with an estimated time to event of 34.6
months. Univariate Cox regression analysis confirmed this finding,
showing a significant hazard ratio of 8.41 (95% confidence interval
(CI) 1.52 – 46.6, p= .015) for the occurrence of an event in TARP-
high patients. Multivariate analysis did not show an association
betweenTARP expression andEFS (Table S4, http://links.lww.com/
HS/A77). However, association with EFS did remain significant
when including all diagnostic pedAML patients, irrespective of the
treatment protocol (n=27/29, hazard ratio 3.83 (95% CI 1.1 –
13.0), p= .032). No significant correlation was found between the
level ofTARP expression andOS (hazard ratio 3.90 (95%CI 0.35–
43.9), p= .27, Fig. 2D).
In conclusion, we here confirm that both TRGC1- and
TRGC2-encoded TARP transcripts co-exist in AML. We
demonstrate that TARP presentation on leukemic cells may
induce beneficial immune responses in pedAML patients. We
consolidate our previous finding that all FLT3-ITD positive
pedAML patients display TARP overexpression, though also
conclude that TARP overexpression is not exclusive for FLT3-
ITD mutated patients. Furthermore, investigation on the role of
FLT3 inhibitors in TARP-high pedAML patients, and their
impact on TARP expression levels, is warranted. TARP
expression was significantly inversely correlated with EFS in a
small cohort of NOPHO-DBH AML2012-treated patients. The
hypothesis that TARPhigh/FLT3-WT pedAML patients may
define a (till now undetectable) poor prognosis group with HR
genetic lesions (KMT2A-SEPT9) and poor outcome will require
further evaluation. Although promising, these data need
confirmation in larger, preferentially multicenter cohorts.4Disclosures
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